Evidence map›Paper›PMID 40896833›Full record

ArticleDiabetes2025

Proteogenomic Discovery of Novel Open Reading Frames With HLA Immune Presentation on Human β-Cells.

Kathryn Walters, Roberto Castro-Gutierrez, Soumyadeep Sarkar, Amber Baldwin, Alexandra S Baker, Ali H Shilleh, Amanda M Anderson, Maki Nakayama, Tim Fugman, Ernesto S Nakayasu and 2 more

Abstract read
In one paragraph

Article in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Kathryn WaltersDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO.
Roberto Castro-GutierrezBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO.
Soumyadeep SarkarBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA.
Amber BaldwinDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO.
Alexandra S BakerDiabetes Institute, University of Florida, Gainesville, FL.
Ali H ShillehBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO.
Amanda M AndersonBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO.
Maki NakayamaBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO.
Tim FugmanInstitute of Biochemistry, Justus-Liebig-Universität Gießen, Gießen, Germany.
Ernesto S NakayasuBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA.
Neelanjan MukherjeeDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0003-0017-1400
Holger A RussBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0001-5117-2927

Funding

Renewal of the Human Islet Research Enhancement Center (HIREC) for the Type-1-Diabetes-Focused Human Islet Research Network (HIRN).U24DK104162 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI John S. Kaddis, Joyce Carol Niland · 2019 to 2026
$12.3M
Molecular Dissection of Insulin Targeting in Anti-Islet AutoimmunityR01DK099317 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI AARON W MICHELS, Maki Nakayama · 2013 to 2026
$5.3M
Alternative RNA splicing events contribute to the onset of islet dysfunction in T1DU01DK127505 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI NAKAYASU, ERNESTO SATOSHI, SUSSEL, LORI · 2020 to 2023
$2.9M
Mechanistic analysis of TDP-43-mediated RNA localization in neurons and its misregulation in ALSR01NS122911 · NINDS · UNIVERSITY OF COLORADO DENVER · PI Holger A. Russ, Jefferson Matthew Taliaferro · 2023 to 2026
$2.3M
Local immune modulation for beta cell replacement therapy in type 1 diabetesR01DK132387 · NIDDK · UNIVERSITY OF FLORIDA · PI PHELPS, EDWARD, RUSS, HOLGER A. · 2022 to 2025
$2.1M
Temporal coordination of stimulus-induced gene expression by RNA-binding proteinsR35GM147025 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI Neelanjan Mukherjee · 2022 to 2026
$1.9M
Systematic validation of biomarkers predictive of IA and T1D and their relationship with disease developmentR01DK138335 · NIDDK · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI Thomas O Metz, Ernesto Satoshi Nakayasu · 2024 to 2026
$1.9M
Boettcher Foundation AWD-103075DOE DE-AC05-76RLO01830Endocrine Society 1000317291-NSFGRFP-WaltersEnvironmental Molecular Sciences LaboratoryJuvenile Diabetes Research Foundation (JDRF)National Science Foundation Graduate Research FellowshipNIDDK/HIRN R01DK12044NIDDK/HIRN R01DK132387NIDDK/HIRN R01NS122911NIDDK/HIRN SCR_014393NIDDK/HIRN UC24 DK104162NIDDK NIH HHS R01 DK099317NIDDK NIH HHS R01 DK132387NIDDK NIH HHS R01 DK138335NIDDK NIH HHS U01 DK127505NIDDK NIH HHS U24 DK104162NIGMS NIH HHS R35 GM147025NIH HHS 1R35GM147025-01NINDS NIH HHS R01 NS122911Pacific Northwest National Laboratory (PNNL) in RichlandSRA 2-SRA-2023-1313-S-BSRA 3-SRA-2023-1367-S-BThe University of Colorado Anschutz Medical CampusUniversity of Colorado Anschutz Medical CampusU.S. Department of Energy (DOE)
6 · The paper itself

Abstract

Ribosome profiling (Ribo-seq) measures translational regulation and reveals novel or unannotated open reading frames (nuORFs) otherwise difficult to identify. Recent reports demonstrate that nuORFs regulate gene expression and immune recognition, highlighting their emerging biological roles. Pancreatic β-cells are critical for maintaining euglycemic conditions, and β-cell impairment contributes to diabetes development. Identification of nuORF and protein/peptide products in human β-cells could reveal novel mechanisms that regulate β-cell function during homeostatic and disease conditions. Here, we applied a proteogenomic approach to human β-cells to define previously unknown protein/peptide products. First, we applied cell type-specific Ribo-seq to map the translatome of human stem cell-derived β-cells (sBCs). Pathways crucial for β-cell function and antigen presentation were subject to translational regulation. We detected a recently described immunogenic neoantigen, INS-DRiP, presumably originating from a downstream start site in INS mRNA. Moreover, our analysis revealed 965 novel nuORFs in sBCs, with a majority showing protein-level support. Comparison with primary human islets further validated nuORF translation and highlighted β-cell specificity. We identified a novel, primate-specific regulatory upstream ORF within TYK2, which is crucial for β-cell function and interferon response and has many variants strongly associated with type 1 diabetes. Finally, we used immunopeptidomics, HLA-binding prediction models, and T-cell coculture assays to validate the presentation and immunogenicity of preproinsulin peptides and nuORFs. Our findings underscore the importance of translational regulation in β-cell function and provide an important resource to the diabetes research community. ARTICLE HIGHLIGHTS: We developed a cell type-specific proteogenomic approach to reveal novel or unannotated open reading frames (nuORFs) using transcriptomics, ribosomal profiling, and proteomic analysis of human pancreatic β-cells using stem cell-derived β-cells and/or cadaveric islets. Our analysis revealed translational regulation of β-cell-specific pathways during differentiation and identified 965 nuORFs, with a majority exhibiting protein support and substantial β-cell specificity. A primate-specific ORF located in the 5' untranslated region of the type 1 diabetes risk gene TYK2 may act as a translational activator. We provide HLA class I immunopeptidomic data from cytokine-stimulated human β-cells and demonstrate their utility in coculture assays with autoreactive T-cell transductants. Taken together, our results define the human β-cell translatome, an important resource to the research field.

Indexed as

Antigen PresentationHLA AntigensInsulin-Secreting CellsOpen Reading FramesProteogenomicsHumansHLA Antigens

Identifiers

PMID40896833
PMCPMC12645175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.